Elicio Therapeutics (ELTX) Gross Margin (2020 - 2021)
Elicio Therapeutics (ELTX) reported Gross Margin of 98.28% for Q4 2021, down 738.0% on a YoY basis from 15.4% in Q4 2020, and down 1.72% quarter-over-quarter from 100.0% in Q3 2021.
Elicio Therapeutics (ELTX) Gross Margin (2020 - 2021) Analysis & Trends
Elicio Therapeutics has reported Gross Margin for 2 years, with the latest figure at 98.28% in Q4 2021.
- For the quarter ending Q4 2021, Gross Margin fell 738.0% year-over-year to 98.28%; the trailing twelve-month figure through Dec 2021 stood at 98.43% (down 17866.0% YoY), and the FY2022 full-year result was 100.0%, up 157.0% from the prior year.
- Gross Margin for Q4 2021 stood at 98.28%, down from 100.0% in the prior quarter.
- The five-year high for Gross Margin was 105.66% in Q4 2020, with the low at 54.32% in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 79.04% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 86.85% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Elicio Therapeutics | 70.12 Mn | 55.17 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 98.28% |
| Sep 30, 2021 | 100.00% |
| Jun 30, 2021 | 100.00% |
| Mar 31, 2021 | 100.00% |
| Dec 31, 2020 | 105.66% |
| Sep 30, 2020 | 57.92% |
| Jun 30, 2020 | 54.32% |